Search results
Author(s):
Martin B Leon
Added:
4 months ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic…
View more
Author(s):
Jennifer S Li
,
YT Chen
,
Claire Morgan
,
et al
Added:
3 years ago
Overview
Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a rare, debilitating, and often fatal lysosomal storage disease. It is caused by an autosomal recessively inherited deficiency of the enzyme acid α-glucosidase (GAA) that hydrolyzes glycogen to glucose in the lysosome; the deficiency causes the deposition of glycogen in multiple tissues,…
View more
Author(s):
Heather Currie
,
Christine Williams
Added:
3 years ago
Cardiovascular disease (CVD) is the leading cause of death in both men and women, yet the extent of the problem in women is frequently underestimated and, compared with men, women are less likely to be offered interventions, are less likely to be represented in clinical trials and have a worse prognosis. This article aims to examine the extent of the problem of CVD in women, summarise the…
View more
Author(s):
Mirvat Alasnag
Added:
1 year ago
ESC Congress 22 —In this short and practice-focused review, Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, Jeddah, SA) shares her thoughts about 3 late ESC hot trials that will have an impact on her practice as an interventionalist cardiologist.
Trials covered in detail include:
00:18: REVIVED-BCIS2:Study of Efficacy and Safety of Percutaneous Coronary Intervention (PCI) to Improve…
View more
Author(s):
Niklas Dyrby Johansen
Added:
10 months ago
ESC-HFA 23 – We are joined onsite by Dr Niklas Dyrby Johansen (Herlev and Gentofte Hospital, DK) to discuss the late-breaking results of the NUDGE-FLU trial in a cohort of patients with cardiovascular disease (CVD) (NCT05542004).
NUDGE-FLU is a prospective, randomized, open-label implementation trial that enrolled over 96,0000 patients across Denmark. The study population included individuals…
View more
Early Management of Hypertension
Author(s):
Deborah L Nadler
,
Athena Poppas
Added:
3 years ago
Article
Author(s):
Mirvat Alasnag
,
Khaled Al-Shaibi
Added:
7 months ago
ESC 23 — We are joined by Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (The King Fahd Armed Forces Hospital, SA) for an insightful wrap-up of the first day of ESC Congress 2023.
New data releases covered in detail include:
BUDAPEST-CRT
FIRE
ECLS-SHOCK
STOP-DAPT 3
Recorded on-site at ESC Congress 2023, Amsterdam.
Editors: Mirjam Boros and Jordan Rance
Video Specialists: Dan Brent, Tom…
View more
Author(s):
Robert A Vogel
Added:
3 years ago
There are about 65 million Americans (or 20–25% of the population) with hypertension.As a top line figure that is probably a little low as it uses the rather strict definition of high blood pressure as being 140 over 90.Hypertension is also very strongly age-related, and as we get older that frequency goes up a lot. Essentially, 95% of Americans will be hypertensive in their lifetime. It is a…
View more
Author(s):
Hisham A Badreldin
,
Khalid bin Saleh
,
Majed Al-Yami
Added:
3 years ago
WRAP-IT
The Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT) was a prospective multicenter study to determine the safety and efficacy of an absorbable surgical mesh envelope containing two antibiotics (minocycline and rifampin) in reducing infection incidence in patients with cardiac implantable electronic devices compared to standard care.1 Approximately 7,000…
View more
Author(s):
Rachel Lampert
,
Michael Ackerman
,
Sharlene Day
Added:
1 year ago
ACC.23/WCC—We are joined onsite by principal investigator Dr Rachel Lampert (Yale School of Medicine, US), Dr Sharlene Day (Penn Medicine, US) and Dr Michael Ackerman (Mayo Clinic, US) to discuss the late-breaking findings from the LIVE-HCM Study. In this trial, investigators aimed to determine the effects of lifestyle and exercise on the well-being of patients with hypertrophic cardiomyopathy …
View more